Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum
Descripción general
Resumen del artículo
The guidance recommends pharmacologic VTE prophylaxis for all hospitalized COVID-19 patients, suggests increased doses for critically ill patients, and advises against routine extended prophylaxis post-discharge. It also recommends using anti-Xa assays to monitor unfractionated heparin and suggests against using D-dimer to guide therapy.
Explícamelo como si tuviera cinco años
Scientists found that people with COVID-19 in the hospital can get blood clots, so doctors give them special medicine to stop these tiny blockages from forming, especially if they are very sick.
Posibles conflictos de intereses
Some authors disclosed receiving grant funding or consulting fees from pharmaceutical companies.
Limitaciones identificadas
Explicación de la calificación
This paper provides important interim guidance on a critical issue during the COVID-19 pandemic. Although based on expert opinion and limited data, it offers a structured and rational approach to anticoagulation in COVID-19 patients, addressing key questions and acknowledging limitations. The disclosed conflicts of interest are noted but don't appear to significantly detract from the value of the guidance.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →